T cells require both primary and costimulatory signals for optimal activation. The primary Ag-specific signal is delivered by engagement of the TCR. The second Ag-independent costimulatory signal is mediated by engagement of the T cell surface costimulatory molecule CD28 with its target cell ligand B7. However, many tumor cells do not express these costimulatory molecules. We previously constructed phage display derived F AB , G8, and Hyb3, Ab-based receptors with identical specificity but distinct affinities for HLA-A1/MAGE-A1, i.e., "TCR-like" specificity. These chimeric receptors comprised the Fc⑀RI-␥ signaling element. We analyzed whether linking the CD28 costimulation structure to it (␥ ؉ CD28) could affect the levels of MHC-restricted cytolysis and/or cytokine production. Human scFv-G8 POS T lymphocytes comprising the ␥ ؉ CD28 vs the ␥ signaling element alone produced substantially more IL-2, TNF-␣, and IFN-␥ in response to HLA-A1/MAGE-A1 POS melanoma cells. Also a drastic increase in cytolytic capacity of scFv-G8 POS T cells, equipped with ␥ ؉ CD28 vs the ␥-chain alone was observed. 
T umor-associated Ags (1) or MHC class I-presented tumor rejection Ags (TRA) 3 (2, 3) can be targeted by CTL-expressing (chimeric) single chain (sc) or two chain mAbs (4 -10) or TCR (11) (12) (13) (14) (15) (16) , respectively. Most immunotherapeutic strategies targeting TRA aim to induce and enhance the number of tumor-specific T lymphocytes in patients by peptide vaccination, because such cells can have the capacity to lyse (native) tumor cells (17, 18) , and the transfer of such tumor-specific T lymphocytes to patients can have clinical significance (19 -22) . However, the isolation of tumor-specific CTL and their expansion to significant numbers for clinical application on an individual basis is cumbersome and the outcome unpredictable.
We and others developed strategies to permanently graft primary human T lymphocytes with MHC-restricted tumor specificity via retroviral introduction of, e.g., chimeric or nonmodified TCR ␣␤ genes (11) (12) (13) (14) (15) (16) or mAb-based receptors (23, 24) . Engineered primary human T lymphocytes expressing (chimeric) TCRs or two chain TCR-like mAbs display the Ag specificity dictated by the introduced TCR or TCR-like mAb; i.e., they specifically lyse relevant tumor cells and produce cytokines. To become independent of the availability of host-derived or in vitro stimulated tumorspecific CTL (clones) as a source of TCR ␣␤ genes but still target TRA, we generated phage display-derived human mAbs with MHC-restricted TCR-like Ag specificities to genetically retarget human T cells to their tumors (23, 24) . TCR as well as TCR-like Abs clearly differ from classical Abs not only with respect to their MHC restriction of Ag recognition but also with regard to ligand binding affinity, which is generally at least a log phase higher for classical mAb vs TCR-like Abs. We took advantage of the relative ease to adopt phage display libraries to allow for in vitro affinity maturation of these peptide/MHC-specific mAbs. Indeed, affinity maturation of the HLA-A1/MAGE-A1-specific Fab G8 resulted in a hyb3 variant, which displayed an 18-fold higher ligand binding affinity (24) . Primary human T lymphocytes expressing this affinity-matured chimeric two chain Fab receptor showed enhanced in vitro immune functions, i.e., showed significantly higher levels of Ag-triggered production of TNF-␣, IFN-␥, and IL-2, but also tumor cell lysis (24) . Here we explored whether specific immune responses of T cells expressing chimeric single chain TCR-like (scFv) receptors could be further enhanced by linking the CD28 costimulatory domain to the ␥-chain signaling element in both low and high affinity TCR-like scFv POS T lymphocytes. To this end, we used scFv rather than two chain TCR-like receptor genes because this approach allows the introduction of scFv vs two chain TCR-like genes with higher efficiency. Primary human T lymphocytes with CD28 ϩ ␥ signaling elements vs ␥ alone showed a significantly enhanced specific anti-tumor response, also at low TRA densities on tumor cells, and produce higher levels of the TNF-␣, IFN-␥, and IL-2 cytokines.
Materials and Methods

Cells and antibodies
T lymphocytes derived from healthy donors were isolated and expanded as described (25) . Target cell lines used in this study are: 1) the native MAGE-A1 POS , HLA-A1 POS melanoma cell line MZ2-MEL 3.0 (MEL3.0); 2) the MAGE-A1 NEG , HLA-A1 POS melanoma cell line MZ2-MEL 2.2 (MEL2.2) (kindly provided by T. Boon and P. Coulie, Ludwig Center Research Center, Brussels, Belgium) (26); 3) the HLA-A1 POS B-LCL APD; and 4) the erythroid leukemia cell line K562. The human embryonic kidney cell line 293T (27) (kindly provided by Y. Soneoka, Department of Biochemistry, Oxford University, Oxford, U.K.,) and phoenix-amph (28) (kindly provided by G. Nolan, Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA) were used as packaging cell lines for the pBullet scFv-␥ and scFv-␥ ϩ CD28 retroviral vectors. Abs that were used in this study were anti-CD3 mAb OKT3 (Ortho Diagnostics) and anti-CD28 (CLB Amsterdam).
Construct synthesis and retroviral gene transfer
Constructs containing chimeric receptors (Fig. 1) were generated in two steps. First, the genes encoding the Fab G8 or Hyb3 H and L chain fragments (23, 24) were subjected to PCR to introduce restriction sites that allow gene insertion into the pBlue-212 vector (12) . Second, the scFv G8 and scFv Hyb3 were introduced into the pBullet retroviral vector (12) , either 5Ј to a ␥ ϩ CD28 fragment, which was derived from the scFv-SP6␥ ϩ CD28 construct (29) , or 5Ј to a fragment comprising the CD4 transmembrane domain and the intracellular domain of Fc⑀RI-␥ (23) resulting in the low affinity receptor vectors pBullet scFvG8-␥ ϩ CD28 and pBullet scFvG8-␥, and the high affinity receptor vectors pBullet scFvHyb3-␥ ϩ CD28, pBullet scFvHyb3-␥, respectively.
These low and high affinity scFv receptor genes were introduced into OKT3-activated primary human T lymphocytes by retronectin-enhanced supernatant transduction, essentially as described (23) . Chimeric receptorexpressing T cells were then expanded in medium supplemented with rIL-2 (30).
Flow cytometry and enrichment of receptor-expressing T cells
To assess the expression of low and high affinity scFv-␥ ϩ CD28 and scFv-␥ receptors on gene-transduced primary human T lymphocytes, 0.5 ϫ 10 6 cells were stained for 30 min at 4°C with saturating concentrations (11 nM final) of PE-labeled HLA-A1/MAGE-A1 tetramers, as described (12) . The dot plots show viable T lymphoblast gated on forward (FSC) and sideward (SSC) light scatter signals. Analysis was performed on a FACScan instrument (BD Biosciences). To enrich for chimeric receptor-expressing T lymphocytes, transduced T lymphocytes were first incubated with PE-labeled HLA-A1/MAGE-A1 tetramers, followed by anti-PE-coated magnetic beads. Tetramer-binding T cells were subsequently obtained by magnetic separation using Miltenyi miniMacs columns (Miltenyi Biotec) according to the manufacturer's instructions. Recombinant IL-2 (10 IU/ml) was present during the entire enrichment procedure.
Cytotoxicity assays
Cytolytic activities of enriched low and high affinity scFv-␥ ϩ CD28 or scFv-␥-transduced human T lymphocytes were measured in 51 Cr release assays at indicated times, as described elsewhere (12) . Peptide loading of target cells was performed by addition of MAGE-A1 nonapeptide (EADPTGHSY; Leiden University Medical Center, Leiden, The Netherlands) or an irrelevant influenza peptide derived from influenza virus A nucleoprotein (CTELKLSDY; Leiden University Medical Center) to target cells 5-15 min before incubation with effector T lymphocytes. The percentage of specific 51 Cr release was calculated as follows: ((test counts Ϫ spontaneous counts)/(maximum counts Ϫ spontaneous counts)) ϫ 100%. Experiments were performed in triplicate, and the SD did not exceed 10%.
TNF-␣, IFN-␥, and IL-2 ELISA
To quantify secreted TNF-␣, IFN-␥, and IL-2, transduced and enriched human T lymphocytes (6 ϫ 10 4 ) were cultured for 24 h either in the presence or absence of 2 ϫ 10 4 adherent tumor cells. When TNF-␣ and IFN-␥ production was assessed, culture medium was supplemented with 360 IU/ml rIL-2, whereas IL-2 production was assessed in medium without exogenous IL-2. Supernatants were harvested and levels of TNF-␣, IFN-␥, and IL-2 were measured by standard ELISA according to the manufacturer's instructions (CLB Amsterdam). Experiments were performed in triplicate, and the SD did not exceed 10%. The t test for means was used to analyze ELISA results.
Results
ScFvG8 (low affinity) and scFvHyb3 (high affinity) comprising either ␥ ϩ CD28 or ␥ signaling elements can be functionally expressed on primary human T lymphocytes
Genes encoding the chimeric receptors scFvG8-␥ ϩ CD28, scFvG8-␥, scFvHyb3-␥ ϩ CD28, and scFvHyb3-␥, specific for HLA-A1/MAGE-A1, were retrovirally introduced into OKT3-activated PBL (Fig. 1) . Cell surface expression of the chimeric low affinity scFvG8-␥ ϩ CD28 and scFvG8-␥ on the one hand and high affinity scFvHyb3-␥ ϩ CD28 and scFvHyb3-␥ TCR-like receptors on the other was demonstrated by PE-labeled HLA-A1/ MAGE-A1 tetramer staining. Over 45% of enriched T cell transductants specifically bound the MAGE-A1/HLA-A1 tetramers ( Fig. 2A) . Expression of the endogenous CD28 coreceptor on anti-CD3-activated gene-transduced T lymphocytes was lacking (Fig.  2B) , as reported for specific Ag-activated T lymphocytes (31). 
FIGURE 2.
A, Low affinity scFvG8-␥, scFvG8-␥ ϩ CD28, and high affinity scFvHyb3-␥, scFvHyb3-␥ ϩ CD28 transduced primary human T lymphocytes specifically bind HLA-A1/MAGE-A1 tetramers. Cell surface expression of the scFv-␥ and scFv-␥ ϩ CD28 receptors on transduced and tetramer-enriched T lymphocytes was analyzed via HLA-A1/MAGE-A1 tetramer staining (A1/ M1; filled histogram). As a control for specific binding, HLA-A1/Flu tetramers were used, which contain a peptide derived from influenza nucleoprotein A (A1 /Flu; open histogram) . B, Absence of CD28 expression on OKT-3 mAbactivated T lymphocytes. Results are shown as histograms. Data acquisition was restricted to viable cells. .2 melanoma cells. The low affinity CD28 ϩ ␥ POS T cell transductants showed increased and specific cytokine production in response to MAGE-A1 POS melanoma cells in comparison with ␥ POS T lymphocytes. High affinity CD28 ϩ ␥ POS T cell transductants also showed higher cytokine production levels in response to MAGE-A1 POS melanoma cells, but this enhanced cytokine response was in part nonspecific because MAGE-A1 NEG Ag lost mutant melanoma cells triggered IFN-␥ and TNF-␣ production, but again production in response to MAGE-A1 POS melanoma cells was still higher (Fig. 3B) (Fig. 4A ).
ScFvG8-␥ ϩ CD28 POS T lymphocytes produce higher amounts of TNF-␣, IFN-␥, and IL-2 in response to melanoma target cells than scFvG8-␥ POS T lymphocytes
Remarkably, significant higher levels of specific target cell lysis by high affinity scFvHyb3-␥ ϩ CD28 POS T lymphocytes were observed, not only of relevant HLA-A1 POS /MAGE-A1 POS melanoma cells, but also of irrelevant K562 and APD target cells, as well as MAGE-A1 NEG Ag lost mutant melanoma cells (Fig. 4B ). When MAGE-A1 NEG Ag lost mutant MZ2-MEL2.2 melanoma target cells were loaded with increasing concentrations of MAGE-A1 peptide (ranging from 1 nM to 10 M) and used as specific target cells, the low affinity scFvG8-␥ ϩ CD28 POS vs scFvG8-␥ POS T lymphocytes showed a significant increased specific lytic capacity. ScFvG8-CD28 ϩ ␥ POS vs scFvG8-␥ POS T lymphocytes required 10-fold less MAGE-A1 Ag at the target cell than scFvG8-␥ POS T lymphocytes for triggering of equal levels of Ag-specific cytolytic activity (Fig. 4C) . High affinity CD28 ϩ ␥ POS T cells also demonstrated enhanced cytolytic activity when compared with the Hyb3-␥ POS T cells, but this enhanced cytolytic activity was only partial specific as non-MAGE-A1 peptide loaded target cells were also lysed (Fig. 4C) .
Discussion
We have in vitro generated class I-HLA-A1/MAGE-A1-specific human CTLs by genetically programming primary human T lymphocytes with low affinity G8 and high affinity Hyb3 receptors comprising the ␥-chain signaling element (23, 24) . These phage display-derived G8 and Hyb3 receptors display a TCR-like specificity, i.e., they recognize MAGE-A1 in the context of class I-HLA-A1. Here we describe the immune response enhancing effects of genetically linking the CD28 costimulation structure to the ␥-chain in low and high affinity receptors (G8 and Hyb3 mAbs, respectively). This was done because first, human tumor cells reportedly lack the B7 ligand for CD28 (32) ; second, we discovered that virtually all human T lymphocytes lack functional expression of the critical costimulatory CD28 molecule following T lymphocyte activation in vitro by anti-CD3 mAb (OKT3), which is required for subsequent gene transduction; third, classic scFv mAbbased receptor POS T lymphocytes, i.e., with MHC nonrestricted Ag recognition, comprising ␥ or ϩ CD28 signaling structures show significant enhanced cytokine production but no enhanced cytolytic capacity (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) .
The immune responses of phage display-derived Ab receptor POS CTLs with TCR-like specificity comprising the combined ␥ ϩ CD28 signaling elements were significantly enhanced, not only at the level of cytokine production triggered by TRA POS stimulator cells, but surprisingly also at the level of TRA-specific target cell lysis. In contrast, human T lymphocyte transductants expressing classic scFv mAb-based receptors comprising ϩ CD28 or only showed increased cytokine production capacity but no increased lytic capacity (37, 42, 44) . The immune responses of these low and high affinity receptor POS T cell transductants with the ␥ ϩ CD28 signaling element, which lack functional expression of CD28 themselves, are efficiently reconstituted by incorporation of the CD28 costimulatory element into the scFv-␥ receptor. Because the CD28 costimulatory element is now built into the scFv-␥ receptor the frequent lack of the B7 ligand expression on tumor cells is bypassed. T lymphocytes expressing low affinity scFvG8 comprising the combined ␥ ϩ CD28 signaling element display significant enhanced production of TNF-␣, IFN-␥, and IL-2 in response to relevant MAGE-A1
POS stimulator cells. The enhanced cytokine production levels may also have relevant consequences in adoptive immunogene therapy because it has been reported that classic MHC nonrestricted scFv Ab-based receptor POS T cell transductants comprising ␥ ϩ CD28 or ϩ CD28 provided animals with increased reduction of tumor mass that appeared IFN-␥ dependent (35, 36, 38) . The tumor-specific induction of, e.g., IL-2 production by scFvG8-␥ ϩ CD28 POS T lymphocytes may bypass the need for exogenous IL-2 in clinical trials to obtain enhanced anti-tumor activity as well as prolonged life span (21, 22, 45) . Reportedly, the life span of human CMV-reactive CTL and adoptively transferred MART1/MelanA or gp100-specific T cell clones was indeed prolonged by the administration of exogenous IL-2 (21, 45) .
The level of immune responses of low affinity scFvG8-␥ ϩ CD28 POS T lymphocytes was comparable to that of high affinity scFv Hyb3-␥ alone receptor POS T lymphocytes and was HLA-A1/ MAGE-A1 specific. However, when the high affinity receptor was engineered to comprise the combined ␥ ϩ CD28, we discovered that they also were triggered by, i.e., nonspecific MAGE-A1 NEG cells, to produce cytokines and lyse the target cells. For example, these high affinity scFvHyb3-␥ ϩ CD28 POS T lymphocyte also lysed MAGE-A1 NEG melanoma cells, APD B-LCL, and K562 myeloid leukemia cells, albeit at lower levels (Fig. 4B) . Like TCRs, TCR-like Abs may display affinities for class I molecules presenting irrelevant peptides (25, 46) . However, the rate of dissociation of nonspecific TCR/MHC complexes is sufficiently high that dissociation always occurs before the nonspecific interaction can activate the TCR-expressing lymphocytes. The difference in dissociation constant between Hyb3 and nonspecific HLA-A1 complexes vs Hyb3 and HLA-A1 molecules presenting MAGE-A1 may be reduced when compared with the dissociation constants of the G8 Ab/HLA-A1 complexes. The consequently prolonged interaction of the Hyb3 receptor with the nonspecific HLA-A1 in combination with the higher triggerable ␥ ϩ CD28 signaling structure results in the "nonspecific" cytolysis and cytokine production.
The affinity maturation of the TCR-like Ab scFvG8 allows the generation of a library of CTL clones with a range of affinities from low to high, based on the use of differential V H V L genes and hence mimics the natural polymorphic T lymphocyte response. The enhancement of the overall immune responses by either affinity maturation of the receptor, linkage of distinct signaling elements together, or combinations thereof will produce T lymphocyte transductants that display distinct TRA triggerabilities: e.g., cytokine production levels and profiles; target cell lytic capacities; and tumor mass penetration abilities. However, as shown here maximum triggerability may result in loss of specificity of the immune response and hence unwanted kill of innocent bystander cells, thereby triggering autoimmune reactions. Therefore, it is mandatory to test these T cell transductants for exquisite Ag specificity before use in clinical therapy protocols.
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